The total medical costs associated with spinal muscular atrophy (SMA) are lower for patients diagnosed at birth via newborn…
Articles by Marisa Wexler, MS
The newborn screening program at Cadham Provincial Laboratory in Manitoba, Canada, is expanding to include spinal muscular atrophy (SMA),…
Among adults with spinal muscular atrophy (SMA) type 3, those with greater motor impairment tend to score better on…
The U.S. Food and Drug Administration (FDA) has extended its approval of Evrysdi (risdiplam) to treat babies with spinal muscular…
A committee of the Canadian Agency for Drugs and Technologies in Health (CADTH) has issued a draft recommendation advising…
Treatment with Spinraza (nusinersen) modestly improved muscle strength and stabilized motor function for adults with spinal muscular atrophy…
For parents, protecting the health and well-being of a child with spinal muscular atrophy (SMA) was a top priority…
Children with spinal muscular atrophy (SMA) type 1 who started treatment with Evrysdi (risdiplam) in the first months of…
Treatment with the experimental muscle-directed therapy apitegromab improved motor function for many of the children and young adults with…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…